BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kahan BD. Sirolimus: a comprehensive review. Expert Opin Pharmacother. 2001;2:1903-1917. [PMID: 11825325 DOI: 10.1517/14656566.2.11.1903] [Cited by in Crossref: 93] [Cited by in F6Publishing: 81] [Article Influence: 4.9] [Reference Citation Analysis]
Number Citing Articles
1 Radovancevic B, Vrtovec B. Sirolimus therapy in cardiac transplantation. Transplantation Proceedings 2003;35:S171-6. [DOI: 10.1016/s0041-1345(03)00229-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 1] [Article Influence: 0.9] [Reference Citation Analysis]
2 Olyaei AJ, Demattos AM, Bennett WM. Cardiovascular complications of immunosuppressive agents in renal transplant recipients. Expert Opin Drug Saf 2005;4:29-44. [PMID: 15709896 DOI: 10.1517/14740338.4.1.29] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
3 Shalev I, Selzner N, Shyu W, Grant D, Levy G. Role of regulatory T cells in the promotion of transplant tolerance. Liver Transpl. 2012;18:761-770. [PMID: 22523007 DOI: 10.1002/lt.23458] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
4 Salabei JK, Hill BG. Implications of autophagy for vascular smooth muscle cell function and plasticity. Free Radic Biol Med 2013;65:693-703. [PMID: 23938401 DOI: 10.1016/j.freeradbiomed.2013.08.003] [Cited by in Crossref: 60] [Cited by in F6Publishing: 51] [Article Influence: 7.5] [Reference Citation Analysis]
5 Johnston L, Florek M, Armstrong R, McCune JS, Arai S, Brown J, Laport G, Lowsky R, Miklos D, Shizuru J, Sheehan K, Lavori P, Negrin R. Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation. Bone Marrow Transplant 2012;47:581-8. [PMID: 21552302 DOI: 10.1038/bmt.2011.104] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 2.9] [Reference Citation Analysis]
6 Toniatti C, Bujard H, Cortese R, Ciliberto G. Gene therapy progress and prospects: transcription regulatory systems. Gene Ther 2004;11:649-57. [DOI: 10.1038/sj.gt.3302251] [Cited by in Crossref: 103] [Cited by in F6Publishing: 85] [Article Influence: 6.1] [Reference Citation Analysis]
7 Kasiske BL, Nashan B, Del Carmen Rial M, Raffaele P, Russ G, Campistol J, Pescovitz MD, Keown PA. A prospective, multinational pharmacoepidemiological study of clinical conversion to sirolimus immunosuppression after renal transplantation. J Transplant 2012;2012:107180. [PMID: 22934151 DOI: 10.1155/2012/107180] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
8 Salas-Ambrosio PJ, Bernad-Bernad MJ, Linares-Alba MA, García-Santisteban R, Tonix-Aburto LA, Ornelas-Lobato GJ, Gracia-Mora I, Rivera-Huerta M, Sánchez-Bartez F, Rico-Morales H, García-Sánchez GA. Toxicity Evaluation of a Novel Rapamycin Liposomal Formulation After Subconjunctival and Intravitreal Injection. J Ocul Pharmacol Ther 2021;37:261-76. [PMID: 33691483 DOI: 10.1089/jop.2020.0108] [Reference Citation Analysis]
9 Vassiliadis J, Bracken C, Matthews D, O'Brien S, Schiavi S, Wawersik S. Calcium mediates glomerular filtration through calcineurin and mTORC2/Akt signaling. J Am Soc Nephrol 2011;22:1453-61. [PMID: 21784900 DOI: 10.1681/ASN.2010080878] [Cited by in Crossref: 34] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
10 Lui SL, Tsang R, Chan KW, Zhang F, Tam S, Yung S, Chan TM. Rapamycin attenuates the severity of established nephritis in lupus-prone NZB/W F1 mice. Nephrology Dialysis Transplantation 2008;23:2768-76. [DOI: 10.1093/ndt/gfn216] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 4.3] [Reference Citation Analysis]
11 Josef F, Marina K, Alois W. Sirolimus myopathy. Transplantation 2003;76:1773-4. [DOI: 10.1097/01.tp.0000090752.85709.9f] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
12 Thipparaboina R, Khan W, Domb AJ. Eluting combination drugs from stents. International Journal of Pharmaceutics 2013;454:4-10. [DOI: 10.1016/j.ijpharm.2013.07.005] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
13 Liu YX, Jin LM, Zhou L, Xie HY, Jiang GP, Chen H, Zheng SS. Sirolimus attenuates reduced-size liver ischemia-reperfusion injury but impairs liver regeneration in rats. Dig Dis Sci. 2010;55:2255-2262. [PMID: 19856103 DOI: 10.1007/s10620-009-1002-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
14 Camardo J. The Rapamune era of immunosuppression 2003: the journey from the laboratory to clinical transplantation. Transplantation Proceedings 2003;35:S18-24. [DOI: 10.1016/s0041-1345(03)00356-7] [Cited by in Crossref: 27] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
15 Wang SC, Pashkovetsky E, Conti D, Ata A, Torosoff M, Fein S, Chandolias N, Lopez-Soler RI, Lyubarova R. Pericardial Effusion After Renal Transplantation: Timing and Clinical Characteristics. Transplant Proc 2021;53:1606-10. [PMID: 33966877 DOI: 10.1016/j.transproceed.2021.03.021] [Reference Citation Analysis]
16 Smith KJ, Hamza S, Skelton H. Histologic features in primary cutaneous squamous cell carcinomas in immunocompromised patients focusing on organ transplant patients. Dermatol Surg. 2004;30:634-641. [PMID: 15061848 DOI: 10.1111/j.1524-4725.2004.30149.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 1.4] [Reference Citation Analysis]
17 Cicora F, Lausada N, Vasquez DN, Cicora P, Zalazar G, Gonzalez P, Palti G, Raimondi C. Sirolimus in kidney transplant donors and clinical and histologic improvement in recipients: rat model. Transplant Proc 2010;42:365-70. [PMID: 20172351 DOI: 10.1016/j.transproceed.2009.11.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
18 Benčina M, Mavrič T, Junkar I, Bajt A, Krajnović A, Lakota K, Žigon P, Sodin-šemrl S, Kralj-iglič V, Iglič A. The Importance of Antibacterial Surfaces in Biomedical Applications. Elsevier; 2018. pp. 115-65. [DOI: 10.1016/bs.abl.2018.05.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 2] [Article Influence: 5.3] [Reference Citation Analysis]
19 Johnston LJ, Brown J, Shizuru JA, Stockerl-Goldstein KE, Stuart MJ, Blume KG, Negrin RS, Chao NJ. Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2005;11:47-55. [PMID: 15625544 DOI: 10.1016/j.bbmt.2004.10.004] [Cited by in Crossref: 102] [Cited by in F6Publishing: 83] [Article Influence: 6.4] [Reference Citation Analysis]
20 Debray D, Furlan V, Baudouin V, Houyel L, Lacaille F, Chardot C. Therapy for acute rejection in pediatric organ transplant recipients. Paediatr Drugs 2003;5:81-93. [PMID: 12529161 DOI: 10.2165/00128072-200305020-00002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
21 Hoyer PF. Late withdrawal of calcineurin inhibitors and switch to mTOR inhibitors - beneficial or too late?: Editorial. Pediatric Transplantation 2011;15:767-9. [DOI: 10.1111/j.1399-3046.2011.01587.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
22 Pescovitz MD, Nezakatgoo N, Lorber MI, Nashan B, Tedesco-Silva H Jr, Kasiske BL, de la Cruz FJ, Russ G, Campistol J, Keown PA; International Sirolimus Study Group. Prospective observational study of sirolimus as primary immunosuppression after renal transplantation. Transplantation 2009;88:1010-8. [PMID: 19855247 DOI: 10.1097/TP.0b013e3181b9d0da] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
23 Vollenbröker B, George B, Wolfgart M, Saleem MA, Pavenstädt H, Weide T. mTOR regulates expression of slit diaphragm proteins and cytoskeleton structure in podocytes. Am J Physiol Renal Physiol 2009;296:F418-26. [PMID: 19019920 DOI: 10.1152/ajprenal.90319.2008] [Cited by in Crossref: 87] [Cited by in F6Publishing: 75] [Article Influence: 6.7] [Reference Citation Analysis]
24 Lee K, Bajwa A, Freitas-Neto CA, Metzinger JL, Wentworth BA, Foster CS. A comprehensive review and update on the non-biologic treatment of adult noninfectious uveitis: part I. Expert Opin Pharmacother 2014;15:2141-54. [PMID: 25226529 DOI: 10.1517/14656566.2014.948417] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
25 Pascual J, Marc??n R, Ortu??o J. Clinical Experience with Everolimus (Certican): Optimizing Dose and Tolerability: . Transplantation 2005;79:S80-4. [DOI: 10.1097/01.tp.0000162433.34739.61] [Cited by in Crossref: 27] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
26 Bhattacharjee S, Brayden DJ. Addressing the challenges to increase the efficiency of translating nanomedicine formulations to patients. Expert Opin Drug Discov 2021;16:235-54. [PMID: 33108229 DOI: 10.1080/17460441.2021.1826434] [Reference Citation Analysis]
27 Aubel D, Fussenegger M. Mammalian synthetic biology - from tools to therapies. Bioessays 2010;32:332-45. [DOI: 10.1002/bies.200900149] [Cited by in Crossref: 31] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
28 Boratyńska M, Banasik M, Watorek E, Falkiewicz K, Patrzałek D, Szyber P, Klinger M. Conversion to sirolimus from cyclosporine may induce nephrotic proteinuria and progressive deterioration of renal function in chronic allograft nephropathy patients. Transplant Proc 2006;38:101-4. [PMID: 16504675 DOI: 10.1016/j.transproceed.2005.12.023] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 2.6] [Reference Citation Analysis]
29 Lechler RI, Garden OA, Turka LA. The complementary roles of deletion and regulation in transplantation tolerance. Nat Rev Immunol 2003;3:147-58. [DOI: 10.1038/nri1002] [Cited by in Crossref: 182] [Cited by in F6Publishing: 156] [Article Influence: 10.1] [Reference Citation Analysis]
30 Lui SL, Yung S, Tsang R, Zhang F, Chan KW, Tam S, Chan TM. Rapamycin prevents the development of nephritis in lupus-prone NZB/W F1 mice. Lupus 2008;17:305-13. [PMID: 18413412 DOI: 10.1177/0961203307088289] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 3.2] [Reference Citation Analysis]
31 Strom T, Haschke M, Boyd J, Roberts M, Arabshahi L, Marbach P, Christians U. Crossreactivity of Isolated Everolimus Metabolites With the Innofluor Certican Immunoassay for Therapeutic Drug Monitoring of Everolimus. Therapeutic Drug Monitoring 2007;29:743-9. [DOI: 10.1097/ftd.0b013e31815b3cbf] [Cited by in Crossref: 20] [Cited by in F6Publishing: 2] [Article Influence: 1.4] [Reference Citation Analysis]
32 Zhang YL, Bendrick-peart J, Strom T, Haschke M, Christians U. Development and Validation of a High-Throughput Assay for Quantification of the Proliferation Inhibitor ABT-578 Using LC/LC-MS/MS in Blood and Tissue Samples: . Therapeutic Drug Monitoring 2005;27:770-8. [DOI: 10.1097/01.ftd.0000185766.52126.bd] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
33 Bennett WM. Immunosuppression with Mycophenolic Acid: One Size Does Not Fit All. JASN 2003;14:2414-6. [DOI: 10.1097/01.asn.0000087540.41388.ad] [Cited by in Crossref: 28] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
34 Sakata N, Yoshimatsu G, Kodama S. The Spleen as an Optimal Site for Islet Transplantation and a Source of Mesenchymal Stem Cells. Int J Mol Sci 2018;19:E1391. [PMID: 29735923 DOI: 10.3390/ijms19051391] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 4.3] [Reference Citation Analysis]
35 Neu V, Delmotte N, Kobold U, Dülffer T, Herrmann R, von der Eltz H, Huber CG. On-line solid-phase extraction high-performance liquid chromatography-tandem mass spectrometry for the quantitative analysis of tacrolimus in whole blood hemolyzate. Anal Bioanal Chem 2012;404:863-74. [DOI: 10.1007/s00216-012-6201-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
36 Marquet P, Åsberg A. Individualizing Transplant Therapy. Individualized Drug Therapy for Patients. Elsevier; 2017. pp. 255-79. [DOI: 10.1016/b978-0-12-803348-7.00016-2] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
37 Ahsan N, Rao KV. Renal Transplantation Update
Series Editors: V. Ram Peddi and M. Roy First: Hepatobiliary Diseases After Kidney Transplantation Unrelated to Classic Hepatitis Virus. Seminars in Dialysis 2002;15:358-65. [DOI: 10.1046/j.1525-139x.2002.00087.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
38 Hartenbach S, Daoud-El Baba M, Weber W, Fussenegger M. An engineered L-arginine sensor of Chlamydia pneumoniae enables arginine-adjustable transcription control in mammalian cells and mice. Nucleic Acids Res 2007;35:e136. [PMID: 17947334 DOI: 10.1093/nar/gkm652] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 3.1] [Reference Citation Analysis]
39 Budde K, Neumayer H, Lehne G, Winkler M, Hauser IA, Lison A, Fritsche L, Soulillou J, Fauchald P, Dantal J. Tolerability and steady-state pharmacokinetics of everolimus in maintenance renal transplant patients. Nephrology Dialysis Transplantation 2004;19:2606-14. [DOI: 10.1093/ndt/gfh322] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
40 Egenolf DD, Rafferty P, Brosnan K, Walker M, Jordan J, Makropoulos D, Kavalkovich K, Watson S, Johns L, Volk A, Bugelski PJ. Development of a murine model of lymph node metastases suitable for immunotoxicity studies. Journal of Pharmacological and Toxicological Methods 2011;63:236-49. [DOI: 10.1016/j.vascn.2010.12.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
41 Ro AJ, Falotico R, Davé V. Microstructure and drug-release studies of sirolimus-containing poly(lactide-co-glycolide) films. J Biomed Mater Res 2011;97B:30-9. [DOI: 10.1002/jbm.b.31777] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
42 Imanguli MM, Pavletic SZ, Guadagnini J, Brahim JS, Atkinson JC. Chronic graft versus host disease of oral mucosa: Review of available therapies. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology 2006;101:175-83. [DOI: 10.1016/j.tripleo.2005.08.028] [Cited by in Crossref: 53] [Cited by in F6Publishing: 39] [Article Influence: 3.5] [Reference Citation Analysis]
43 Wu M, Chang C, Hung C. Rapamycin in patients with chronic renal allograft dysfunction. Clin Transplant 2005;19:236-42. [DOI: 10.1111/j.1399-0012.2005.00329.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
44 Smith KJ, Hamza S, Skelton H. Histologic Features in Primary Cutaneous Squamous Cell Carcinomas in Immunocompromised Patients Focusing on Organ Transplant Patients: . Dermatologic Surgery 2004;30:634-41. [DOI: 10.1097/00042728-200404020-00011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
45 Saemann MD, Zeyda M, Stulnig TM, Bohmig GA, Wekerle T, Horl WH, Zlabinger GJ. Janus kinase-3 (JAK3) inhibition: a novel immunosuppressive option for allogeneic transplantation. Transplant Int 2004;17:481-9. [DOI: 10.1111/j.1432-2277.2004.tb00476.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
46 Romagnoli J, Citterio F, Nanni G, Tondolo V, Castagneto M. Severe limb lymphedema in sirolimus-treated patients. Transplant Proc 2005;37:834-6. [PMID: 15848548 DOI: 10.1016/j.transproceed.2004.12.180] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
47 Klawitter J, Bendrick-Peart J, Rudolph B, Beckey V, Klawitter J, Haschke M, Rivard C, Chan L, Leibfritz D, Christians U, Schmitz V. Urine metabolites reflect time-dependent effects of cyclosporine and sirolimus on rat kidney function. Chem Res Toxicol 2009;22:118-28. [PMID: 19099400 DOI: 10.1021/tx800253x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 3.8] [Reference Citation Analysis]
48 Ro AJ, Falotico R, Davé V. Morphological and degradation studies of sirolimus-containing poly(lactide-co-glycolide) discs. J Biomed Mater Res 2012;100B:767-77. [DOI: 10.1002/jbm.b.32510] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
49 Ozturk H, Terzi A, Ozturk H, Kukner A. Effect of sirolimus on renal injury induced by bile duct ligation in rats. Acta Cir Bras. 2010;25:401-406. [PMID: 20877949 DOI: 10.1590/s0102-86502010000500004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
50 Ostojic M, Sagic D, Jung R, Zhang YL, Nedeljkovic M, Mangovski L, Stojkovic S, Debeljacki D, Colic M, Beleslin B, Milosavljevic B, Orlic D, Topic D, Karanovic N, Paunovic D, Christians U; NOBORI PK Investigators. The pharmacokinetics of Biolimus A9 after elution from the Nobori stent in patients with coronary artery disease: the NOBORI PK study. Catheter Cardiovasc Interv 2008;72:901-8. [PMID: 19016466 DOI: 10.1002/ccd.21775] [Cited by in Crossref: 41] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
51 Yoon KH. Proliferation Signal Inhibitors for the Treatment of Refractory Autoimmune Rheumatic Diseases: A New Therapeutic Option. Annals of the New York Academy of Sciences 2009;1173:752-6. [DOI: 10.1111/j.1749-6632.2009.04663.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
52 Zwart ES, Yüksel E, Pannekoek A, de Vries R, Mebius RE, Kazemier G. De Novo Carcinoma after Solid Organ Transplantation to Give Insight into Carcinogenesis in General-A Systematic Review and Meta-Analysis. Cancers (Basel) 2021;13:1122. [PMID: 33807849 DOI: 10.3390/cancers13051122] [Reference Citation Analysis]
53 de Mare-Bredemeijer EL, Metselaar HJ. Optimization of the use of Calcineurin inhibitors in liver transplantation. Best Pract Res Clin Gastroenterol. 2012;26:85-95. [PMID: 22482528 DOI: 10.1016/j.bpg.2012.01.017] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
54 Kim E, Yoon SY, Shin YJ. Oxidative Stress in Cornea. In: Babizhayev MA, Li DW, Kasus-jacobi A, Žorić L, Alió JL, editors. Studies on the Cornea and Lens. New York: Springer; 2015. pp. 3-22. [DOI: 10.1007/978-1-4939-1935-2_1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
55 Webster AC, Lee VW, Chapman JR, Craig JC. Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients. Cochrane Database Syst Rev 2006;:CD004290. [PMID: 16625599 DOI: 10.1002/14651858.CD004290.pub2] [Cited by in Crossref: 28] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
56 Nguyen QD, Ibrahim MA, Watters A, Bittencourt M, Yohannan J, Sepah YJ, Dunn JP, Naor J, Shams N, Shaikh O, Leder HA, Do DV. Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: primary 6-month results of the SAVE Study. J Ophthalmic Inflamm Infect 2013;3:32. [PMID: 23514595 DOI: 10.1186/1869-5760-3-32] [Cited by in Crossref: 54] [Cited by in F6Publishing: 55] [Article Influence: 6.8] [Reference Citation Analysis]
57 Roy D, Dittmer DP. Phosphatase and tensin homolog on chromosome 10 is phosphorylated in primary effusion lymphoma and Kaposi's sarcoma. Am J Pathol 2011;179:2108-19. [PMID: 21819957 DOI: 10.1016/j.ajpath.2011.06.017] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
58 Morales JM. Influence of the new immunosuppressive combinations on arterial hypertension after renal transplantation. Kidney Int Suppl 2002;:S81-7. [PMID: 12410861 DOI: 10.1046/j.1523-1755.62.s82.16.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
59 Chueh SC, Kahan BD. Clinical application of sirolimus in renal transplantation: an update. Transpl Int. 2005;18:261-277. [PMID: 15730485 DOI: 10.1111/j.1432-2277.2004.00039.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 2.2] [Reference Citation Analysis]
60 Emond JC. What’s new in transplantation. Journal of the American College of Surgeons 2002;194:636-41. [DOI: 10.1016/s1072-7515(02)01161-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
61 Mok KW, Mruk DD, Cheng CY. Regulation of blood-testis barrier (BTB) dynamics during spermatogenesis via the "Yin" and "Yang" effects of mammalian target of rapamycin complex 1 (mTORC1) and mTORC2. Int Rev Cell Mol Biol 2013;301:291-358. [PMID: 23317821 DOI: 10.1016/B978-0-12-407704-1.00006-3] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
62 Stern RM, Berliner N. Targeting the mTOR pathway in idiopathic multicentric Castleman disease. J Clin Invest 2019;129:4086-8. [PMID: 31524635 DOI: 10.1172/JCI131332] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Foroncewicz B, Mucha K, Paczek L, Chmura A, Rowinski W. Efficacy of rapamycin in patient with juvenile rheumatoid arthritis. Transplant Int 2005;18:366-8. [DOI: 10.1111/j.1432-2277.2004.00070.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.3] [Reference Citation Analysis]
64 Hogan WJ, Little MT, Zellmer E, Friedetzky A, Diaconescu R, Gisburne S, Lee R, Kuhr C, Storb R. Postgrafting immunosuppression with sirolimus and cyclosporine facilitates stable mixed hematopoietic chimerism in dogs given sublethal total body irradiation before marrow transplantation from DLA-identical littermates. Biol Blood Marrow Transplant 2003;9:489-95. [PMID: 12931117 DOI: 10.1016/s1083-8791(03)00148-4] [Cited by in Crossref: 34] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
65 Steudel W, Dingmann C, Zhang Y, Bendrick-peart J, Clavijo C, Shulze J, Betts R, Christians U. Randomized, Double-Blind, Placebo-Controlled, Single Intravenous Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the Novel Coronary Smooth Muscle Cell Proliferation Inhibitor Biolimus A9 in Healthy Individuals. The Journal of Clinical Pharmacology 2011;51:29-39. [DOI: 10.1177/0091270010361255] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
66 Antin JH. Approaches to graft-vs-host disease. Pediatric Transplantation 2005;9:71-5. [DOI: 10.1111/j.1399-3046.2005.00441.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
67 Ghiggeri GM, Bruschi M, Musante L, Candiano G, Boccardi C, Citti L, Rastaldi MP, Mangraviti S, Rosso G, Larti A, Rosati A, Urbani A, Gusmano R, Bertoni E, Salvadori M. Post-transplant proteinuria associated with everolimus: Definition of main features with proteomics. Prot Clin Appl 2008;2:1327-37. [DOI: 10.1002/prca.200780162] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
68 Bharate SS, Vishwakarma RA. Impact of preformulation on drug development. Expert Opin Drug Deliv 2013;10:1239-57. [PMID: 23534681 DOI: 10.1517/17425247.2013.783563] [Cited by in Crossref: 22] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
69 Ponticelli C, Tarantino A, Aroldi A, Sparacino V, Stefoni S, Citterio F, Duca L, Scolari M, Calabrese S, Altieri P, Civati G, Cesana B. Design of a trial comparing sirolimus plus mycophenolate mofetil versus sirolimus plus cyclosporine. Transplantation Proceedings 2003;35:S62-3. [DOI: 10.1016/s0041-1345(03)00212-4] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
70 S�emann MD, Zeyda M, Stulnig TM, B�hmig GA, Wekerle T, H�rl WH, Zlabinger GJ. Janus kinase-3 (JAK3) inhibition: a novel immunosuppressive option for allogeneic transplantation. Transpl Int 2004;17:481-9. [DOI: 10.1007/s00147-004-0756-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
71 Webster A, Higgins G, Chapman J, Craig J, Webster A. Sirolimus and everolimus for kidney transplant recipients. The Cochrane Database of Systematic Reviews. Chichester: John Wiley & Sons, Ltd; 1996. [DOI: 10.1002/14651858.cd004290] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
72 Barten MJ, Streit F, Boeger M, Dhein S, Tarnok A, Shipkova M, Armstrong VW, Mohr FW, Oellerich M, Gummert JF. Synergistic effects of sirolimus with cyclosporine and tacrolimus: analysis of immunosuppression on lymphocyte proliferation and activation in rat whole blood. Transplantation. 2004;77:1154-1162. [PMID: 15114077 DOI: 10.1097/01.tp.0000120391.42712.e8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
73 Sreejith SL, Aswathy BP, Joseph R, Sasi R. Size exclusion chromatography: An effective tool for the estimation of Sirolimus levels. Journal of Chromatography B 2020;1156:122303. [DOI: 10.1016/j.jchromb.2020.122303] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 Mctaggart RA, Gottlieb D, Brooks J, Bacchetti P, Roberts JP, Tomlanovich S, Feng S. Sirolimus Prolongs Recovery from Delayed Graft Function After Cadaveric Renal Transplantation: Sirolimus Prolongs Recovery from DGF. American Journal of Transplantation 2003;3:416-23. [DOI: 10.1034/j.1600-6143.2003.00078.x] [Cited by in Crossref: 147] [Cited by in F6Publishing: 124] [Article Influence: 8.2] [Reference Citation Analysis]
75 Gomez-Cambronero J. Rapamycin inhibits GM-CSF-induced neutrophil migration. FEBS Lett 2003;550:94-100. [PMID: 12935893 DOI: 10.1016/s0014-5793(03)00828-7] [Cited by in Crossref: 64] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
76 Levy G, Schmidli H, Punch J, Tuttle-Newhall E, Mayer D, Neuhaus P, Samuel D, Nashan B, Klempnauer J, Langnas A. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. Liver Transpl. 2006;12:1640-1648. [PMID: 16598777 DOI: 10.1002/lt.20707] [Cited by in Crossref: 105] [Cited by in F6Publishing: 84] [Article Influence: 7.5] [Reference Citation Analysis]
77 Ostojic MC, Perisic Z, Sagic D, Jung R, Zhang Y, Bendrick-peart J, Betts R, Christians U; on behalf of the Stealth PK Investigators. The pharmacokinetics of Biolimus A9 after elution from the BioMatrix II stent in patients with coronary artery disease: The Stealth PK Study. Eur J Clin Pharmacol 2011;67:389-98. [DOI: 10.1007/s00228-010-0895-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
78 Thervet E, Martinez F, Legendre C. Benefit-Risk Assessment of Ciclosporin Withdrawal in Renal Transplant Recipients: . Drug Safety 2004;27:457-76. [DOI: 10.2165/00002018-200427070-00003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
79 Lui SL, Chan KW, Tsang R, Yung S, Lai KN, Chan TM. Effect of rapamycin on renal ischemia-reperfusion injury in mice. Transplant Int 2006;19:834-9. [DOI: 10.1111/j.1432-2277.2006.00361.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 2.1] [Reference Citation Analysis]
80 Donauer J, Rumberger B, Klein M, Faller D, Wilpert J, Sparna T, Schieren G, Rohrbach R, Dern P, Timmer J, Pisarski P, Kirste G, Walz G. Expression profiling on chronically rejected transplant kidneys1. Transplantation 2003;76:539-47. [DOI: 10.1097/01.tp.0000079459.89608.b7] [Cited by in Crossref: 43] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
81 Cho Y, Ha ES, Baek IH, Kim MS, Cho CW, Hwang SJ. Enhanced supersaturation and oral absorption of sirolimus using an amorphous solid dispersion based on Eudragit® e. Molecules 2015;20:9496-509. [PMID: 26020699 DOI: 10.3390/molecules20069496] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]